CYLEMBIO Trademark

Trademark Overview


On Wednesday, September 20, 2023, a trademark application was filed for CYLEMBIO with the United States Patent and Trademark Office. The USPTO has given the CYLEMBIO trademark a serial number of 79382512. The federal status of this trademark filing is REGISTERED as of Tuesday, February 25, 2025. This trademark is owned by IO Biotech ApS. The CYLEMBIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; pharmaceutical drugs and pharmaceutical substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; synthetic peptides for pharmaceutical use for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, horm...
cylembio

General Information


Serial Number79382512
Word MarkCYLEMBIO
Filing DateWednesday, September 20, 2023
Status700 - REGISTERED
Status DateTuesday, February 25, 2025
Registration Number7699741
Registration DateTuesday, February 25, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; pharmaceutical drugs and pharmaceutical substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; synthetic peptides for pharmaceutical use for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIO Biotech ApS
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDK

Party NameIO Biotech ApS
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDK

Party NameIO Biotech ApS
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDK

Trademark Events


Event DateEvent Description
Friday, November 10, 2023APPLICATION FILING RECEIPT MAILED
Thursday, November 2, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, November 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 18, 2023ASSIGNED TO EXAMINER
Wednesday, December 20, 2023NON-FINAL ACTION WRITTEN
Thursday, December 21, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, January 2, 2024REFUSAL PROCESSED BY MPU
Tuesday, January 2, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, January 23, 2024REFUSAL PROCESSED BY IB
Wednesday, January 31, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 31, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 29, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, February 29, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, February 29, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, February 29, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, February 29, 2024SUSPENSION LETTER WRITTEN
Thursday, February 29, 2024LETTER OF SUSPENSION E-MAILED
Thursday, February 29, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, October 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 17, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, October 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 24, 2024ASSIGNED TO LIE
Wednesday, December 11, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 1, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 7, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 7, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 25, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, February 25, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, March 31, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Monday, March 31, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Saturday, April 19, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Thursday, September 11, 2025FINAL DISPOSITION PROCESSED
Thursday, September 11, 2025FINAL DISPOSITION NOTICE SENT TO IB
Friday, October 3, 2025FINAL DECISION TRANSACTION PROCESSED BY IB
Sunday, May 25, 2025FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB